Trial Profile
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 14 Apr 2018 Results of deep sequencing analysis using patients from placebo controlled arm (n=42) from this study, presented at The International Liver Congress 2018.
- 02 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Sep 2013 Planned end date changed from 1 Apr 2013 to 1 Jan 2016 as reported by ClinicalTrials.gov.